Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

Clinical Trial of Recombinant RSV Vaccine (CHO Cell) (Adjuvanted) in Chinese Population Aged 18 Years and Older.

22 maja 2026 zaktualizowane przez: Ab&B Bio-tech Co., Ltd.JS

A Randomized, Blinded, Controlled Phase I/II Clinical Trial to Evaluate the Safety and Immunogenicity of a Recombinant Respiratory Syncytial Virus Vaccine (CHO Cell) (Adjuvanted) in Adults Aged 18 Years and Older.

The primary objective of the phase I trial is to evaluate the safety and tolerability of different doses of the recombinant respiratory syncytial virus vaccine (CHO cell) (Adjuvanted) in adults aged 18 years and older, with the secondary objective being to assess its immunogenicity. The primary objectives of the phase II trial are to evaluate the immunogenicity and safety of the recombinant respiratory syncytial virus vaccine (CHO cell) (Adjuvanted) with different adjuvant ratios in adults aged 60 years and older, with the secondary objective being to evaluate the persistence of immune responses.

Przegląd badań

Typ studiów

Interwencyjne

Zapisy (Szacowany)

470

Faza

  • Faza 2
  • Faza 1

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Kontakt w sprawie studiów

Lokalizacje studiów

    • Sichuan
      • Zigong, Sichuan, Chiny
        • Rekrutacyjny
        • Zigong Center for Disease Control and Prevention
        • Kontakt:
        • Główny śledczy:
          • Ting Huang, Bachelor

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

  • Dorosły
  • Starszy dorosły

Akceptuje zdrowych ochotników

Tak

Opis

Inclusion Criteria:

  • Males or females aged 18 years and older at the time of enrollment (aged 18 years and older for the phase I part; aged 60 years and older for the phase II part), who are able to provide legal proof of identity.
  • Voluntarily agree to participate in the trial, able to fully understand and sign the informed consent form.
  • Able to attend all scheduled follow-up visits and comply with the requirements of the clinical trial protocol to complete the study.
  • Female participants must meet the following criteria: In the phase I part, women of childbearing potential* must have a negative pregnancy test prior to enrollment and be willing to use effective contraceptive measures for 12 months after receiving the investigational vaccine; in the phase II part, only women of non-childbearing potential will be enrolled.

    • Women of childbearing potential: Defined as females who have experienced menarche and have not yet entered menopause, unless permanently sterile, such as documented bilateral salpingectomy, bilateral oophorectomy, or hysterectomy; menopause is defined as amenorrhea for 12 consecutive months without other medical cause.

[Effective contraceptive measures include: oral contraceptives, injectable contraceptives, subdermal implants or hormonal patches, intrauterine device (IUD), sterilization surgery, abstinence (no sexual intercourse), male condoms, etc.; rhythm method, withdrawal, and emergency contraception are not considered effective contraceptive measures.]

  • Axillary body temperature ≤ 37.0°C measured on site prior to vaccination on the day of vaccination.

Exclusion Criteria:

  • Clinically significant laboratory abnormalities that, in the investigator's comprehensive judgment, preclude enrollment (applicable only to the phase I part).
  • Pregnant or breastfeeding women.
  • A clear diagnosis of RSV infection or a history of RSV infection-related respiratory disease within 6 months prior to vaccination.
  • Use of immunoglobulins or/and any blood products or plasma derivatives within 3 months prior to vaccination, or planned use during the study.
  • Treatment with immunomodulators (including immunosuppressants and immunostimulants) within 6 months prior to vaccination (e.g., long-term use of systemic glucocorticoids for ≥14 days at a dose of ≥2 mg/kg/day or ≥20 mg/day prednisone or equivalent) (excluding inhaled, intra-articular, and topical steroids).
  • Administration or planned use of long-acting immunomodulatory drugs (e.g., infliximab) at any time during the study.
  • A history of severe allergic reactions (e.g., anaphylactic shock, allergic laryngeal edema, Henoch-Schönlein purpura, thrombocytopenic purpura, Arthus reaction) following any previous vaccination or drug use, or a family history of severe allergies.
  • Impaired immune function or a diagnosis of congenital or acquired immunodeficiency, or human immunodeficiency virus (HIV) infection.
  • A personal or family history of convulsions, epilepsy, encephalopathy, psychiatric disorders, or neurological diseases (such as Guillain-Barré syndrome, Miller Fisher syndrome).
  • A diagnosis of lymphoproliferative disease or malignant tumor within 5 years.
  • Clinically significant electrocardiogram (ECG) abnormalities as determined by the investigator (applicable only to the phase I part).
  • Previous vaccination with any licensed or investigational RSV vaccine prior to enrollment, or planned vaccination during the study.
  • Receipt of any vaccine within 14 days prior to vaccination, or any live vaccine within 30 days prior to vaccination.
  • An acute disease or an acute exacerbation of a chronic disease within 3 days prior to vaccination, or use of antipyretic, analgesic, or anti-allergy medications.
  • Suspected or known alcohol abuse or alcohol dependence (referring to a drinking pattern that causes serious mental or physical health problems) or drug abuse.
  • A history of thrombocytopenia or other coagulation disorders that may contraindicate intramuscular injection.
  • Severe or unstable chronic diseases, including but not limited to cardiovascular diseases [e.g., hypertension uncontrolled by medication (on-site blood pressure measurement prior to vaccination: systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg), coronary heart disease, myocarditis, pericarditis, atrial fibrillation], metabolic diseases (e.g., poorly controlled diabetes), hematological disorders (e.g., severe anemia, hemophilia), hepatic or renal diseases, digestive system diseases, respiratory system diseases (e.g., chronic obstructive pulmonary disease, active pulmonary tuberculosis, other severe respiratory diseases).

Note: For participants aged 60 years and older, those with pre-existing stable disease may be enrolled. This is defined as participants who may have underlying conditions such as hypertension or diabetes, provided that symptoms and signs are stable and medically controllable as assessed by the investigator prior to vaccination, and who have not required changes to the treatment/medication regimen or hospitalization due to the underlying condition within 3 months.

  • A history of confirmed immune-mediated/autoimmune diseases (e.g., cold agglutinin hemolytic anemia, lymphadenopathy, eosinophilia, systemic lupus erythematosus, gout, hyperuricemia, acute disseminated encephalomyelitis, immune thrombocytopenia, autoimmune aplastic anemia, autoimmune neutropenia, autoimmune lymphoproliferative syndrome, thrombocytopenic purpura).
  • Asplenia or functional asplenia, as well as any condition resulting in asplenia or splenectomy.
  • Currently participating in or planning to participate in another clinical study involving investigational or unregistered products (drugs, vaccines, medical devices, etc.) during this study.
  • Any other condition that, in the investigator's judgment, makes the individual unsuitable for participation in this clinical trial.

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Zapobieganie
  • Przydział: Randomizowane
  • Model interwencyjny: Przydział równoległy
  • Maskowanie: Poczwórny

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Komparator placebo: Grupa placebo
The vaccine is administered as a single 0.5 mL intramuscular injection into the deltoid muscle of the upper arm on Day 0.
Eksperymentalny: Investigational Vaccine 1 (Low Dose) Group
The vaccine is administered as a single 0.25 mL intramuscular injection into the deltoid muscle of the upper arm on Day 0.
Eksperymentalny: Investigational Vaccine 2 (Low Dose) Group
The vaccine is administered as a single 0.25 mL intramuscular injection into the deltoid muscle of the upper arm on Day 0.
The vaccine is administered as a single 0.5 mL intramuscular injection into the deltoid muscle of the upper arm on Day 0.
Eksperymentalny: Investigational Vaccine 1 Group
The vaccine is administered as a single 0.5 mL intramuscular injection into the deltoid muscle of the upper arm on Day 0.
Eksperymentalny: Investigational Vaccine 2 Group
The vaccine is administered as a single 0.25 mL intramuscular injection into the deltoid muscle of the upper arm on Day 0.
The vaccine is administered as a single 0.5 mL intramuscular injection into the deltoid muscle of the upper arm on Day 0.
Eksperymentalny: Investigational Vaccine 3 Group
The vaccine is administered as a single 0.5 mL intramuscular injection into the deltoid muscle of the upper arm on Day 0.
Komparator placebo: Adjuvant Control Group
The vaccine is administered as a single 0.5 mL intramuscular injection into the deltoid muscle of the upper arm on Day 0.

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Incidence of solicited (local and systemic) adverse events (AEs) within 14 days post-vaccination.
Ramy czasowe: Within 14 days post-vaccination.
Within 14 days post-vaccination.
Incidence of unsolicited AEs within 30 days post-vaccination.
Ramy czasowe: Within 30 days post-vaccination.
Within 30 days post-vaccination.
Incidence of clinically significant laboratory abnormalities(blood biochemistry, blood routine, coagulation function, urinalysis) on Day 3 post-vaccination, and incidence of clinically significant ECG abnormalities on Days 3, 14, and 30 post-vaccination.
Ramy czasowe: On Days 3, 14, and 30 post-vaccination
Applicable to Phase I only
On Days 3, 14, and 30 post-vaccination
Incidence of serious adverse events (SAEs) and adverse events of special interest (AESIs) within 12 months post-vaccination.
Ramy czasowe: Within 12 months post-vaccination.
Within 12 months post-vaccination.
At 1 month post-vaccination: geometric mean titer (GMT) of neutralizing antibodies against RSV-A and RSV-B.
Ramy czasowe: At 1 month post-vaccination
Applicable to Phase Ⅱ only
At 1 month post-vaccination
At 1 month post-vaccination: seroresponse rate (SRR) of neutralizing antibodies against RSV-A and RSV-B.
Ramy czasowe: At 1 month post-vaccination
Applicable to Phase Ⅱ only
At 1 month post-vaccination
At 1 month post-vaccination: geometric mean fold rise (GMFR) of neutralizing antibodies against RSV-A and RSV-B.
Ramy czasowe: At 1 month post-vaccination
Applicable to Phase Ⅱ only
At 1 month post-vaccination
At 1 month post-vaccination: geometric mean concentration (GMC) of pre-F specific IgG antibodies against both RSV-A and RSV-B subtypes.
Ramy czasowe: At 1 month post-vaccination
Applicable to Phase Ⅱ only
At 1 month post-vaccination
At 1 month post-vaccination: SRR of pre-F specific IgG antibodies against both RSV-A and RSV-B subtypes.
Ramy czasowe: At 1 month post-vaccination
Applicable to Phase Ⅱ only
At 1 month post-vaccination
At 1 month post-vaccination: GMFR of pre-F specific IgG antibodies against both RSV-A and RSV-B subtypes.
Ramy czasowe: At 1 month post-vaccination
Applicable to Phase Ⅱ only
At 1 month post-vaccination

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
At 1 month post-vaccination: GMT of neutralizing antibodies against RSV-A and RSV-B.
Ramy czasowe: At 1 month post-vaccination
Applicable to Phase I only
At 1 month post-vaccination
At 1 month post-vaccination: SRR of neutralizing antibodies against RSV-A and RSV-B.
Ramy czasowe: At 1 month post-vaccination
Applicable to Phase I only
At 1 month post-vaccination
At 1 month post-vaccination: GMFR of neutralizing antibodies against RSV-A and RSV-B.
Ramy czasowe: At 1 month post-vaccination
Applicable to Phase I only
At 1 month post-vaccination
At 1 month post-vaccination: GMC of pre-F specific IgG antibodies against both RSV-A and RSV-B subtypes.
Ramy czasowe: At 1 month post-vaccination
Applicable to Phase I only
At 1 month post-vaccination
At 1 month post-vaccination: SRR of pre-F specific IgG antibodies against both RSV-A and RSV-B subtypes.
Ramy czasowe: At 1 month post-vaccination
Applicable to Phase I only
At 1 month post-vaccination
At 1 month post-vaccination: GMFR of pre-F specific IgG antibodies against both RSV-A and RSV-B subtypes.
Ramy czasowe: At 1 month post-vaccination
Applicable to Phase I only
At 1 month post-vaccination
At 14 days, 6 months, 12 months, and 24 months post-vaccination: GMT of neutralizing antibodies against RSV-A and RSV-B.
Ramy czasowe: At 14 days, 6 months, 12 months, and 24 months post-vaccination
Applicable to Phase Ⅱ only
At 14 days, 6 months, 12 months, and 24 months post-vaccination
At 14 days, 6 months, 12 months, and 24 months post-vaccination: SRR of neutralizing antibodies against RSV-A and RSV-B.
Ramy czasowe: At 14 days, 6 months, 12 months, and 24 months post-vaccination
Applicable to Phase Ⅱ only
At 14 days, 6 months, 12 months, and 24 months post-vaccination
At 14 days, 6 months, 12 months, and 24 months post-vaccination: GMFR of neutralizing antibodies against RSV-A and RSV-B.
Ramy czasowe: At 14 days, 6 months, 12 months, and 24 months post-vaccination
Applicable to Phase Ⅱ only
At 14 days, 6 months, 12 months, and 24 months post-vaccination
At 14 days, 6 months, 12 months, and 24 months post-vaccination: GMC of pre-F specific IgG antibodies against both RSV-A and RSV-B subtypes.
Ramy czasowe: At 14 days, 6 months, 12 months, and 24 months post-vaccination
Applicable to Phase Ⅱ only
At 14 days, 6 months, 12 months, and 24 months post-vaccination
At 14 days, 6 months, 12 months, and 24 months post-vaccination: SRR of pre-F specific IgG antibodies against both RSV-A and RSV-B subtypes.
Ramy czasowe: At 14 days, 6 months, 12 months, and 24 months post-vaccination
Applicable to Phase Ⅱ only
At 14 days, 6 months, 12 months, and 24 months post-vaccination
At 14 days, 6 months, 12 months, and 24 months post-vaccination: GMFR of pre-F specific IgG antibodies against both RSV-A and RSV-B subtypes.
Ramy czasowe: At 14 days, 6 months, 12 months, and 24 months post-vaccination
Applicable to Phase Ⅱ only
At 14 days, 6 months, 12 months, and 24 months post-vaccination
At 14 days, 1 month, and 6 months post-vaccination: counts of CD4+ and CD8+ T cells expressing at least two activation markers (IFN-γ, IL-2, TNF-α, CD40L)
Ramy czasowe: At 14 days, 1 month, and 6 months post-vaccination
Applicable to Phase Ⅱ only
At 14 days, 1 month, and 6 months post-vaccination

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Współpracownicy

Śledczy

  • Główny śledczy: Ting Huang, Bachelor, Sichuan Center for Disease Control and Prevention

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Rzeczywisty)

14 maja 2026

Zakończenie podstawowe (Szacowany)

14 września 2027

Ukończenie studiów (Szacowany)

14 sierpnia 2029

Daty rejestracji na studia

Pierwszy przesłany

29 kwietnia 2026

Pierwszy przesłany, który spełnia kryteria kontroli jakości

6 maja 2026

Pierwszy wysłany (Rzeczywisty)

13 maja 2026

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

27 maja 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

22 maja 2026

Ostatnia weryfikacja

1 maja 2026

Więcej informacji

Terminy związane z tym badaniem

Plan dla danych uczestnika indywidualnego (IPD)

Planujesz udostępniać dane poszczególnych uczestników (IPD)?

NIE

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Nie

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Subskrybuj